SGLT2i use linked to lower risk for neurodegenerative disease in T2DM
By
HealthDay News
Sep 18, 2024
A reduced risk for Alzheimer’s disease, vascular dementia and Parkinson’s disease was seen with SGLT2i use in type 2 diabetes.
SGLT-2 inhibitors may cut dementia risk in patients with diabetes
By
Haymarket Media
Sep 03, 2024
The findings show a greater effect with longer treatment, compared with dipeptidyl peptidase-4 inhibitors.
Is Eli Lilly using ‘granfluencers’ to raise awareness of its Alzheimer’s med?
By
Marc Iskowitz
Sep 04, 2024
Here’s why older internet celebs — granfluencers — soon might be making rounds on the Alzheimer’s drug marketing scene.
No spike in schizophrenia, other diagnoses among people with dementia after feds crack down on antipsychotic...
By
Kimberly Marselas
Aug 28, 2024
Federal policies designed to reduce use of antipsychotic medications in nursing homes did not lead to clinically significantly higher rates of schizophrenia diagnoses among people living with dementia,...
Risk for dementia similar with SGLT2 inhibitors, dulaglutide in T2DM
Aug 26, 2024
The estimated risk difference varied from −2.45 to 0.63 percentage points with SGLT2 versus dulaglutide among older adults.
Pandemic challenges raise concerns about assisted living’s ability to care for cognitively impaired...
By
Kimberly Bonvissuto
Aug 15, 2024
Exacerbated challenges faced by memory care assisted living communities during the COVID-19 pandemic may have contributed to the increased use of antipsychotics and antidepressants, raising concerns about...
Benzodiazepines not tied to higher dementia risk in older adults
Jul 16, 2024
Potential class-dependent associations may exist, however.